1. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. (4th May 2018) Authors: Naqash, Abdul Rafeh; Yang, Li V.; Sanderlin, Edward J.; Atwell, Druid C.; Walker, Paul R. Journal: Acta oncologica Issue: Volume 57:Number 5(2018) Page Start: 705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report. (3rd June 2021) Authors: McCallen, Justin D.; Naqash, Abdul Rafeh; Marie, Mona A.; Atwell, Druid C.; Muzaffar, Mahvish; Sharma, Nitika; Amara, Suneetha; Liles, Darla; Walker, Paul R.; Yang, Li V. Journal: Acta oncologica Issue: Volume 60:Number 6(2021) Page Start: 813 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗